icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Barcelona, Spain
13-17 April 2016
Back grey_arrow_rt.gif
 
 
 
Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With
HCV and HIV-1: The ASTRAL-5 Study

 
 
  Reported by Jules Levin
EASL 2016 Barcelona April 14-17
 
David Wyles1, Norbert Brau2,3, Shyam Kottilil4, Eric Daar5, Kimberley Workowski6, Annie Luetkemeyer7, Oluwatoyin Adeyemi8, Peter Ruane9, Brian Doehle10, K.C. Huang10, Anu Osinusi10, John McNally10, Diana M. Brainard10, John G. McHutchison10, Susanna Naggie11, Mark Sulkowski12
 
1Division of Infectious Diseases, University of California, San Diego, California, USA; 2Veteran Affairs Medical Center, New York, New York, USA; 3Icahn School of Medicine at Mount Sinai, New York, New York, USA; 4Institute of Human Virology, University of Maryland, Baltimore, Maryland, USA; 5David Geffen School of Medicine, University of California, Los Angeles, California, USA; 6Emory University, Atlanta, Georgia, USA; 7University of California, San Francisco, California, USA; 8Rush University Medical Center, Chicago, Illinois, USA; 9Ruane Medical and Liver Health Institute, Los Angeles, California, USA; 10Gilead Sciences, Inc., Foster City, California, USA; 11Duke University, Durham, North Carolina, USA; 12Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

EASL1

EASL2

EASL3

EASL4

EASL5

EASL6

EASL7

EASL8

EASL9

EASL10